Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
18-MC Compound · 1 trial · 1 indication
Safety and tolerability will be assessed by the incidence and severity of adverse events (AEs). An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.
| Arm | Type | Description |
|---|---|---|
| 18-MC SAD Study | EXPERIMENTAL | In Part 1, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice in 1 day. |
| 18-MC MAD Study | EXPERIMENTAL | In Part 2, healthy participants will be randomized into cohorts to receive 18-MC HCl or placebo twice a day for 7 consecutive days. |
| Name | Type | Description |
|---|---|---|
| 18-MC Compound | DRUG | 18-MC |
Key Inclusion Criteria: 1. Written informed consent before any study-specific procedures. 2. Healthy male and female volunteers aged 18 to 55 years (inclusive) with suitable veins for cannulation and repeated venipuncture. 3. Female subjects of both childbearing and nonchildbearing potential will b...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
18-MC Compound is an investigational small molecule being developed for the treatment of addiction. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The compound is being studied for its potential to address addictive disorders, though it remains in early-stage clinical testing.
The specific molecular target of 18-MC Compound has not been disclosed in available information. The compound is being studied for its effects in addiction, but its precise mechanism of action has not been publicly detailed. As a small molecule in Phase 1 development, its target remains under investigation.
18-MC Compound is being developed by Definium Therapeutics, Inc., a biopharmaceutical company. The company is publicly traded under the ticker symbol DFTX. Definium Therapeutics is advancing this small molecule through clinical development for the treatment of addiction.
18-MC Compound is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The compound is still in early-stage testing to evaluate its safety and tolerability in human subjects.
18-MC Compound has one completed Phase 1 clinical trial, identified as NCT04292197, titled "A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers." The trial enrolled 108 participants in Australia and was a randomized, double-blind, controlled study involving healthy volunteers aged 18 years and older.
Yes, 18-MC Compound is also known as 18-Methoxycoronaridine, often abbreviated as 18-MC HCl. The clinical trial NCT04292197 specifically assessed 18-Methoxycoronaridine (18-MC HCl) in healthy volunteers, confirming that these names refer to the same investigational compound.